Epididymo-orchitis

PDF

Cause

  • Epididymo-orchitis is the clinical syndrome of pain and swelling of the epididymis and testis which occurs in the context of a urethral or a urinary tract infection.
  • In sexually active men aged 14 – 35 the causative organisms are most commonly Chlamydia trachomatis and Neisseria gonorrhoeae, however men who have insertive anal sex may also acquire enteric Gram-negative bacteria (such as E. Coli).
  • There is weak evidence for the causative role of Mycoplasma genitalium.
  • In younger and older age groups the causative organisms are more likely to be enteric Gram-negative bacteria. 
  • Epididymo-orchitis can also be secondary to a number of other bacterial infections (such as syphilis and tuberculosis) and viral infections (mumps) but this is seen uncommonly in our clinic. 

Clinical Presentation

  • Typically there is unilateral swelling and tenderness of the epididymis which feels indurated on palpation. 
  • In milder infections there may be no involvement of the testis while in more severe infections, or viral orchitis, the testes are also involved.
  • The presence of urethral or lower urinary tract symptoms, systemic symptoms and a more gradual onset helps to distinguish epididymo-orchitis from torsion of the testis, but differentiation is frequently difficult and the clinician needs to have a low threshold for referral. 
  • Differential diagnosis includes:
    • Testicular torsion
    • Torsion of epididymal appendage
    • Trauma
    • Hydrocoele
    • Epididymal cyst
    • Testicular tumour
  • Testicular torsion is a surgical emergency which should be considered in all patients with a painful scrotum.
    • It most commonly occurs in males under the age of 20 but can occur at any age. 
    • If testicular torsion is suspected, the patient should be referred to an emergency department for urgent surgical assessment.  
    • An ultrasound scan with Doppler is helpful diagnostically but should not delay surgical assessment.

Diagnosis

Epididymo-orchitis is a clinical diagnosis, sometimes confirmed on ultrasound scan.
 

Test

Site/Specimen

Comments

Nucleic acid amplification test (NAAT)

First void urine

Test for chlamydia and gonorrhoea

Gram Stain

Urethral swab

Perform if urethral discharge is present (for gram negative intracellular diplococci)

Microscopy, culture and sensitivities

Mid-stream urine

 

Ultrasound with doppler

Testes

A very useful modality in the diagnosis of epididymo-orchitis and to exclude torsion. It may be used to confirm the clinical impression but it should not delay antibiotic treatment or referral to an emergency department if torsion needs to be excluded.

Serology

 

Consider testing for mumps, TB if atypical infection.

 

Management

Index patient

  • Antibiotic treatment depends on the presumed source of infection and should aim to cover the most likely bacterial pathogens.
  • Simple analgesics, scrotal support, limitation of activity, and use of cold packs can be helpful.
  • Patients with acute epididymo-orchitis on appropriate treatment should generally improve within 48 to 72 hours.
  • If there is no improvement the diagnosis should be re-evaluated or referral considered.

Condition

Recommended

Comments

Epididymo-orchitis likely caused by sexually acquired pathogen

Doxycycline 100 mg PO, twice daily for 14 days.

 

If suspect gonorrhoea, add Ceftriaxone 500 mg IM, stat

Alternative to Doxycycline:

Azithromycin 1 g PO, stat, repeated in 1 week

 

Epididymo-orchitis likely caused by urinary tract pathogen

Cephalexin 500mg PO, four times a day for 14 days

OR

Amoxycillin + clavulanate 875+125mg PO, twice daily for 14 days

Alternative antibiotics:

Ciprofloxacin 500mg PO, twice daily for 14 days

OR

Norfloxacin 400mg PO, twice daily for 14 days

 


Disclaimer
The content of these treatment guidelines is for information purposes only. The treatment guidelines are generic in character and should be applied to individuals only as deemed appropriate by the treating practitioner on a case by case basis. Alfred Health, through MSHC, does not accept liability to any person for the information or advice (or the use of such information or advice) which is provided through these treatment guidelines. The information contained within these treatment guidelines is provided on the basis that all persons accessing the treatment guidelines undertake responsibility for assessing the relevance and accuracy of the content and its suitability for a particular patient. Responsible use of these guidelines requires that the prescriber is familiar with contraindications and precautions relevant to the various pharmaceutical agents recommended herein.


Last Updated Feb 2021

Download Word version